AbbVie and Alphabet's Calico added to Operation Warp Speed for rare diseases

Zachary Brennan

Senior Editor

AbbVie and Alphabet’s Calico announced Friday that their potential treatment for the rare neurological disease known as vanishing white matter disease will be part of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie and Alphabet's Calico added to Operation Warp Speed for rare diseases

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

With a $372M megaround, Formation Bio looks to in-license 10+ drugs

Ab­b­Vie and Al­pha­bet's Cal­i­co added to Op­er­a­tion Warp Speed for rare dis­eases

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Ex­clu­sive: To de­vel­op bet­ter cell ther­a­pies for sol­id tu­mors, a new start­up plans to test hun­dreds of them at once

With a $372M megaround, For­ma­tion Bio looks to in-li­cense 10+ drugs

AbbVie and Alphabet's Calico added to Operation Warp Speed for rare diseases

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

With a $372M megaround, Formation Bio looks to in-license 10+ drugs